ROCKVILLE, Md., Oct. 14, 2015 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that Peter D. Suzdak, Ph.D., the Company’s Chief Executive Officer, will present at the 14th Annual BIO Investor Forum on Tuesday, October 20, 2015 at 2:30 p.m. PDT in the Fillmore presentation room at the Palace Hotel in San Francisco, California.
The presentation will be webcast live and can be accessed on the Investor Relations section of the Company’s website, or by accessing the following hyperlink:
http://www.veracast.com/webcasts/bio/investorforum2015/93111159835.cfm
A replay of the webcast will be available on the Investor Relations section of the Company’s website until January 18, 2016.
Hosted by the Biotechnology Industry Organization (BIO), the 14th Annual BIO Investor Forum is a dedicated biotechnology investor conference serving leading private and public biotechnology companies and life sciences investors.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals Inc. (NYSE MKT:RNN) is a clinical stage biopharmaceutical company dedicated to developing novel, best-in-class therapeutics for the treatment of cancer. The Company’s mission is to improve the lives of cancer patients by developing next generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn’s product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth. Pre-clinical studies show that certain of Rexahn’s product candidates may be effective against multiple types of cancer, drug resistant cancers, and difficult-to-treat cancers, and others may augment the effectiveness of current FDA-approved cancer treatments. The Company has a broad oncology pipeline that includes three anti-cancer compounds currently in clinical development: Supinoxin™, RX-3117, and Archexin®, and a novel nanopolymer-based drug delivery platform technology that may increase the bio-availability of FDA-approved chemotherapies. For more information about the Company and its oncology programs, please visit www.rexahn.com.
Help employers find you! Check out all the jobs and post your resume.
